News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Candel Therapeutics
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
April 25, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
April 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
April 09, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
April 04, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
March 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
March 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
March 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
February 13, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
February 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
December 12, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
November 28, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 09, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
November 04, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
November 03, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
October 18, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
September 27, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
September 26, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 10, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
June 13, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
June 08, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 05, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 19, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
May 02, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
April 17, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
March 30, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
February 01, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
January 12, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Tickers
CADL
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.